News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
691,137 Results
Type
Article (39910)
Company Profile (284)
Press Release (650943)
Section
Business (204273)
Career Advice (2022)
Deals (35483)
Drug Delivery (92)
Drug Development (81169)
Employer Resources (169)
FDA (16169)
Job Trends (14875)
News (345446)
Policy (32621)
Tag
Academia (2540)
Alliances (49349)
Alzheimer's disease (1290)
Approvals (16131)
Artificial intelligence (164)
Bankruptcy (355)
Best Places to Work (11627)
Biotechnology (200)
Breast cancer (205)
Cancer (1536)
Cardiovascular disease (124)
Career advice (1683)
CAR-T (106)
Cell therapy (314)
Clinical research (65079)
Collaboration (577)
Compensation (308)
COVID-19 (2663)
C-suite (134)
Data (1472)
Diabetes (190)
Diagnostics (6206)
Earnings (85068)
Employer resources (147)
Events (110416)
Executive appointments (492)
FDA (16945)
Funding (519)
Gene therapy (218)
GLP-1 (629)
Government (4399)
Healthcare (18770)
Infectious disease (2766)
Inflammatory bowel disease (117)
Interviews (312)
IPO (16401)
Job creations (3664)
Job search strategy (1435)
Layoffs (430)
Legal (7925)
Lung cancer (226)
Manufacturing (216)
Medical device (13233)
Medtech (13238)
Mergers & acquisitions (19342)
Metabolic disorders (501)
Neuroscience (1654)
NextGen: Class of 2025 (6521)
Non-profit (4476)
Northern California (1874)
Obesity (285)
Opinion (193)
Patents (137)
People (56797)
Phase I (20251)
Phase II (28656)
Phase III (21385)
Pipeline (618)
Postmarket research (2567)
Preclinical (8564)
Radiopharmaceuticals (239)
Rare diseases (290)
Real estate (5909)
Regulatory (21859)
Research institute (2318)
Resumes & cover letters (353)
Southern California (1617)
Startups (3587)
United States (16693)
Vaccines (633)
Weight loss (199)
Date
Today (115)
Last 7 days (420)
Last 30 days (1946)
Last 365 days (34893)
2025 (1818)
2024 (35331)
2023 (40146)
2022 (51239)
2021 (55816)
2020 (54170)
2019 (46588)
2018 (35077)
2017 (32217)
2016 (31595)
2015 (37612)
2014 (31378)
2013 (26373)
2012 (28610)
2011 (29299)
2010 (27357)
Location
Africa (721)
Arizona (203)
Asia (37514)
Australia (6117)
California (4262)
Canada (1562)
China (365)
Colorado (193)
Connecticut (207)
Europe (80347)
Florida (608)
Georgia (147)
Illinois (414)
Indiana (242)
Maryland (686)
Massachusetts (3292)
Michigan (183)
Minnesota (318)
New Jersey (1191)
New York (1208)
North Carolina (789)
Northern California (1874)
Ohio (155)
Pennsylvania (1001)
South America (1099)
Southern California (1617)
Texas (621)
Utah (121)
Washington State (428)
691,137 Results for "pfizer inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Vaccines
GSK, Pfizer RSV Shots Required to Carry Guillain-Barré Syndrome Warnings
A post-marketing review by the FDA detected an increased risk of the autoimmune condition in patients inoculated with GSK’s Arexvy and Pfizer’s Abrysvo, prompting the regulator to require adjustments to the vaccines’ labels.
January 8, 2025
·
2 min read
·
Tristan Manalac
Phase III
Pfizer’s Ibrance Improves Survival in New Breast Cancer Indication
Pfizer, facing increasing pressure from Novartis, is touting a Phase III win for Ibrance as the first clinical evidence supporting the CDK4/6 inhibitor class’ use in patients with a specific type of breast cancer.
December 12, 2024
·
1 min read
·
Annalee Armstrong
Government
Lilly, Pfizer Execs Sing Optimistic Tune on Incoming Admin After Trump Dinner
A week after dining with Trump and his team at Mar-a-Lago, leaders at Pfizer and Eli Lilly have publicly stated that they intend to collaborate with the incoming administration on key issues affecting the pharma industry.
December 12, 2024
·
2 min read
·
Tristan Manalac
Bladder cancer
Pfizer’s Subcutaneous PD-1 Blocker Aces Phase III in Bladder Cancer, Carves Niche Versus Keytruda
If approved, Pfizer’s sasanlimab will distinguish itself from Merck’s blockbuster Keytruda as the first PD-1 inhibitor indicated in combination with BCG for high-risk non-muscle invasive bladder cancer patients who had not previously undergone BCG treatment.
January 10, 2025
·
2 min read
·
Tristan Manalac
Business
Dispatches From JPM, Biogen’s Sage Buyout Offer, Pfizer’s Obesity Play, More
J&J, GSK, Eli Lilly and others struck high-value transactions in the early days of biopharma’s annual kickoff conference. Meanwhile, Biogen proposes to acquire struggling neuro partner Sage, and obesity dominates discussions as Pfizer goes “all in.”
January 15, 2025
·
1 min read
·
Heather McKenzie
Gene therapy
Sangamo’s Stock Plummets as Pfizer Axes Hemophilia Gene Therapy Pact
Sangamo is on course to run out of money within months and has now lost access to up to $220 million in milestone payments from Pfizer.
January 2, 2025
·
2 min read
·
Nick Paul Taylor
GLP-1
Pfizer Cautiously Optimistic on Obesity Pill as Kailera Challenges Lilly’s Zepbound With Strong Phase II Data
Obesity continues to grab attention at the J.P. Morgan Healthcare Conference in San Francisco, with both Pfizer and Kailera Therapeutics outlining their plans in the space moving forward.
January 14, 2025
·
2 min read
·
Tristan Manalac
Drug development
5 Sickle Cell Therapies to Watch Following Pfizer’s Oxbryta Exit
In the wake of Pfizer’s voluntary market withdrawal of the popular sickle cell disease therapy,
BioSpace
looks at five investigational drugs currently making their way through the pipeline.
October 21, 2024
·
4 min read
·
Kate Goodwin
Executive Appointments
Pfizer Shakes Up C-Suite, Elevating Cancer Chief Boshoff to CSO
Chris Boshoff will take over as Pfizer’s next chief scientific officer as of January 1, replacing Mikael Dolsten who led the pharma through the COVID-19 pandemic. The move comes weeks after Pfizer faced pressure from activist investor Starboard Value.
November 20, 2024
·
2 min read
·
Annalee Armstrong
Drug Development
BridgeBio Wins FDA Approval for ATTR-CM Drug, Launching Competition With Pfizer
BridgeBio secured approval for Attruby Friday, along with the all-important mortality benefit that could give the drug a significant boost in the market against Pfizer’s tafamidis and potentially Alnylam’s Amvuttra.
November 23, 2024
·
8 min read
·
Heather McKenzie
1 of 69,114
Next
